Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sorrento Therapeutics Inc SRNE

Healthcare Biotechnology
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G... see more

Recent & Breaking News (GREY:SRNE)

LifeSci Advisors Initiates Coverage of Sorrento Therapeutics

Marketwired November 11, 2013

Sorrento Therapeutics Enters into Antibody and Vaccine Development Alliance for the Prevention and Treatment of Obesity

PR Newswire November 5, 2013

Sorrento Therapeutics Announces Closing of Public Offering of Common Stock

PR Newswire October 30, 2013

Sorrento Therapeutics Announces Full Exercise of Over-Allotment Option

PR Newswire October 25, 2013

Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ

PR Newswire October 24, 2013

Sorrento Therapeutics Acquires Clinical Stage Drug Candidate for Treatment of Chronic Pain

PR Newswire October 10, 2013

Sorrento Therapeutics Announces a Presentation on Cynviloq(TM) at the AACR Conference on Advances in Ovarian Cancer Research: From Concept to Clinic

PR Newswire September 16, 2013

Sorrento Therapeutics Secures Rights to Biomiga Diagnostics' Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy

PR Newswire September 10, 2013

Sorrento Therapeutics Completes IgDraSol Merger

PR Newswire September 10, 2013

Sorrento Therapeutics to Present at Two Healthcare Conferences

PR Newswire September 6, 2013

Sorrento Therapeutics and IGDRASOL Proceed with Development of Cynviloq(TM) under 505(b)(2) Bioequivalence Regulatory Pathway

PR Newswire August 5, 2013

Sorrento Therapeutics Announces Reverse Split of Common Stock

PR Newswire August 1, 2013

Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies

PR Newswire July 9, 2013

Sorrento Therapeutics, Inc. and IGDRASOL Will Present Preliminary Phase III Data Analysis for Cynviloq at the 4th International Nanomedicine Conference in Sydney, Australia

PR Newswire July 1, 2013

Sorrento Therapeutics Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit

PR Newswire June 24, 2013

Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Basel, Switzerland

PR Newswire June 21, 2013